Press Release

HeartFlow Names Healthcare Industry Veteran Michael Buck as Executive Vice President and Chief Commercial Officer

REDWOOD CITY, Calif. – June 1, 2017 – HeartFlow Inc. has announced the appointment of seasoned healthcare leader Michael Buck as executive vice president and chief commercial officer. Effective immediately, Buck will be responsible for expanding and accelerating global market adoption of the company’s HeartFlow® FFRCT Analysis, the first noninvasive technology to provide insight into both the extent of coronary artery disease and the impact that disease has on blood flow to the heart.

“Mike brings of wealth of valuable commercial leadership experience to HeartFlow at a pivotal growth time for the company,” said John H. Stevens, M.D., chairman and CEO of HeartFlow. “We are thrilled to be adding a professional of his caliber to our executive management team, and look forward to his help in bringing the HeartFlow FFRCT Analysis to every physician and patient who could benefit from it in markets worldwide.”

Buck brings to HeartFlow 25 years of operational experience in global business and product development, licensing and acquisitions, venture investment and commercial sales management. He most recently served as president of the medical products division for Cardinal Health, with global responsibility for the Cardinal brand product portfolio. Prior to Cardinal Health, Buck held several senior leadership roles at Abbott Laboratories, including vice president of global market development, vice president of licensing and acquisitions, and vice president of venture investing. He has also held commercial leadership positions at Novoste Corporation, Boston Scientific and Smith & Nephew.

“HeartFlow’s technology stands to change the way coronary artery disease is diagnosed and managed in health settings across the world,” said Buck. “I am honored to be part of a team with a proven solution that not only improves patient experience and population health, but also drives significant unnecessary cost out of the healthcare system.”

About HeartFlow Inc.

HeartFlow, Inc. is a personalized medical technology company seeking to transform the way cardiovascular disease is diagnosed and treated. The company’s HeartFlow FFRCT Analysis is the first available non-invasive solution that enables a physician to more accurately evaluate whether a patient has significant coronary artery disease (CAD) based on both anatomy and physiology. The solution, which leverages deep learning to create a personalized 3D model of the patient’s arteries, is well positioned to become an integral part of the standard of care for patients who are at risk for CAD because of its potential to improve clinical outcomes, improve the patient experience and reduce the cost of care. The HeartFlow FFRCT Analysis is available in the United States, Canada, Europe and Japan. For more information visit www.heartflow.com.


Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.